Improving treatment and imaging in ADPKD
van Gastel, Maatje Dirkje Adriana

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2019

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
PKD and the vasopressin pathway

Maatje D.A. van Gastel
Vicente E. Torres

Ann Nutr Metab. 2017;70(suppl 1):43–50
Chapter 2

ABSTRACT

Vasopressin, also known as AVP or antidiuretic hormone (ADH), plays a pivotal role in maintaining body homeostasis. Increased vasopressin concentrations, measured by its surrogate copeptin, have been associated with disease severity as well as disease progression in polycystic kidney disease (PKD), and in experimental studies vasopressin has shown to directly regulate cyst growth. Blocking vasopressin effects on the kidney via the vasopressin V2 receptor, or lower circulating vasopressin concentration, are potential treatment opportunities that have been the subject of study in PKD in recent years. Treatment with vasopressin V2 receptor antagonist tolvaptan has been shown to inhibit disease progression in experimental studies, as well as in a large randomized controlled trial involving 1445 patients with autosomal dominant polycystic kidney disease (ADPKD), lowering total kidney volume growth from 5.5% to 2.8% and the slope of the reciprocal of the serum creatinine level from -3.81 to -2.61 [mg per milliliter](−1)/year. Alternatively, lowering circulating vasopressin could delay disease progression. Vasopressin is secreted in response to an increased plasma osmolality, which in turn is caused by a low fluid or high osmolar intake; other lifestyle factors, like smoking, increase vasopressin concentration. Here, we provide a comprehensive review of the physiology as well as pathophysiology of vasopressin in PKD, the promising effects of tolvaptan treatment, and potential synergistic or additive treatments in combination with tolvaptan. We also review current evidence regarding the effect of influencing disease progression in PKD by lifestyle changes, fluid intake in particular.
Polycystic kidney disease and the vasopressin pathway

INTRODUCTION

In this review, we summarize the current evidence about the pathophysiological relation of vasopressin with the progression of polycystic kidney disease (PKD), and give a comprehensive overview of potential treatment options, by either blocking the effect of vasopressin using the kidney specific vasopressin V2 receptor antagonist tolvaptan or lowering circulating vasopressin concentration by changing lifestyle, fluid intake in particular. Due to the journal limitation regarding number of references allowed, we only included papers and reviews conducted in the last ten years.

PHYSIOLOGICAL ACTIONS OF VASOPRESSIN

Arginine vasopressin or AVP is a hormone pivotal to maintain fluid homeostasis in the body, and is secreted after osmotic as well as hemodynamic stimuli. Vasopressin is well-known for its antidiuretic effects in the kidney, but also influences the vascular tonus and is involved in the regulation of the endocrine stress response. There are three pathways by which vasopressin is released. For this review the classical, and most well-known, pathway is relevant. Via this pathway, vasopressin is released directly into the circulation in response to osmotic or hemodynamic stimuli.

There are three different known receptors for vasopressin that are all part of the sub-group rhodopsin, all G-protein-coupled receptors. Via the V1a-receptor, present in many tissues, vasopressin is known to influence hepatic glycogenolysis, platelet aggregation, and vasoconstriction during hypovolemia. The V1b-receptor is found in the adenohypophysis, where it influences ACTH secretion, which stimulates the synthesis and secretion of the adrenocortical hormones cortisol, androgens and aldosterone. The V2 receptor is mainly located in the collecting ducts and the thick ascending limbs of the loops of Henle and plays a pivotal role in body homeostasis because of its antidiuretic effect. Binding of vasopressin to the V2 receptor in the collecting duct increases water permeability and sodium reabsorption, via activation of AQP-trafficking and the epithelial sodium channel (ENaC) respectively.

In 2006, copeptin was introduced as a biomarker for measurement of circulating vasopressin. At the time there was an unmet need to find a biomarker for vasopressin, since vasopressin is a small molecule that is unstable in plasma. Copeptin has been shown to be a reliable surrogate, and has been used in many studies in different fields, including cardiovascular, renal and polycystic kidney disease.
Chapter 2

**PATHOPHYSIOLOGICAL EFFECTS OF VASOPRESSIN IN POLYCYSTIC KIDNEY DISEASE**

Mutations in either the PKD1 and PKD2 gene cause autosomal dominant PKD (ADPKD), whereas mutations in the PKHD1 gene cause autosomal recessive PKD (ARPKD). PKHD1 normally encodes the protein fibrocystin whereas PKD1 and PKD2 encode polycystin-1 (PC1) and polycystin-2 (PC2), respectively. Both disorders are associated with cyst formation in the kidney and are characterized by abnormal excessive fluid secretion, as well as excessive proliferation and apoptosis of the tubular epithelial cells.

Vasopressin is increased in patients with PKD, and the concentration of its surrogate copeptin is associated with disease severity when analyzed cross-sectionally, as well as disease progression measured longitudinally as kidney function decline and kidney growth. It has been shown that vasopressin directly regulates cyst growth in rats orthologous to human ARPKD which phenotypically resembles human ADPKD. After breeding these rats with vasopressin deficient Brattleboro rats, it was shown that rats lacking vasopressin had lower levels of cAMP and that cystogenesis was inhibited almost completely. Administration of the vasopressin V2 receptor agonist DDAVP recovered the full cystic phenotype in these Brattleboro rats.

A urine concentrating defect is thought to be the cause of the increased vasopressin concentration in PKD. Findings of a decreased urine concentrating capacity in an early phase of ADPKD, before renal impairment occurs, strengthen this hypothesis. When analyzing this urine concentrating defect in more detail, Bankir et al. observed that this was a urea-selective concentrating defect by means of a lower urine/plasma (U/P)-urea ratio, whereas no difference in total U/P osmoles- or U/P sodium-ratios compared to healthy controls were observed. This defect is thought to originate in the disruption of the medullary architecture by cysts, which reduces the efficiency of countercurrent exchange of urea.

Lowering the vasopressin effect on the kidney could potentially modify the disease course in ADPKD. This either could be accomplished by blocking the effects of vasopressin in the kidney using a vasopressin V2 receptor specific antagonist like tolvaptan, or could be accomplished by lowering the circulating vasopressin concentration using lifestyle changes such as increased water intake. Recent preclinical studies suggest that additional drugs acting downstream from the vasopressin V2 receptor could enhance and possibly improve the tolerability of vasopressin V2 receptor antagonists and deserve further study. Evidence for these approaches is discussed in the following sections.
Polycystic kidney disease and the vasopressin pathway

TOLVAPTAN AS TREATMENT IN POLYCYSTIC KIDNEY DISEASE

The increased vasopressin and cAMP concentration associated with PKD formed the rationale for exploring the effects of vasopressin V2 receptor antagonists (V2RA). Administration of V2RA OPC31260 led to a lowered renal cAMP, inhibited disease development, and either halted progression or caused regression of established disease in animal models orthologous to the human ARPKD and nephronophthisis (NPH), as well as in mouse models of ADPKD.

In the TEMPO 3:4 Trial, a large randomized controlled study including 1,445 patients with ADPKD, tolvaptan slowed the disease progression of ADPKD after 3 years of treatment, by a lower total kidney volume growth of 2.8% annually versus 5.5% in placebo treated patients (P<0.001), as well as a decreased slope of the reciprocal of the serum creatinine level, -2.61 [mg per milliliter](-1) per year vs. -3.81 [mg per milliliter](-1) per year, in tolvaptan versus placebo treated patients respectively. Patients were eligible if they had an estimated creatinine clearance of ≥60 ml/min. Recent post hoc analyses found similar beneficial effects of tolvaptan in ADPKD across CKD stages 1-3, showed that tolvaptan use lowered albuminuria and monocyte chemotactic protein-1 (MCP-1) excretion, whereas it increased copeptin concentration, and that it significantly lowered the incidence of kidney pain events from 16.8% to 10.1%, with a risk reduction of 36%. A higher albuminuria and a higher copeptin concentration at baseline both predicted renal function decline in placebo- as well as tolvaptan-treated patients, and were both associated with a stronger tolvaptan treatment effect.

DRUGS WITH EFFECTS THAT ARE POTENTIALLY SYNERGISTIC OR ADDITIVE TO THOSE OF TOLVAPTAN

Tolvaptan has been shown to slow disease progression in ADPKD by antagonizing the vasopressin V2 receptor in the kidney (Figure 1), lowering intracellular cAMP, and inhibiting fluid secretion and cell proliferation. By interfering with aquaporin-2 (AQP2) trafficking, however, it induces aquaresis and enhances vasopressin release. Combining tolvaptan with treatments that lower cAMP or increase AQP2 in the apical membrane of principal cells could increase its efficacy and reduce the side effect of aquaresis (Figure 1).

Long-acting somatostatin analogs acting on somatostatin receptors (SSTR) inhibit adenyl cyclase and slow renal and hepatic cyst expansion in murine and small clinical trials of ADPKD. Hopp et al. found an additive efficacy of tolvaptan and pasireotide (a SSTR-1,
Chapter 2

-2, -3 and -5 analogue) compared to either treatment alone, as well as less aquarexis in the combination therapy compared to tolvaptan alone\textsuperscript{18}.

Metformin inhibits complex 1 of the mitochondrial respiratory chain thus reducing ATP production and increasing AMP\textsuperscript{19}. AMP in turn directly inhibits adenylyl cyclase and activates AMPK. Inhibition of adenylyl cyclase\textsuperscript{20} and activation of phosphodiesterase 4B by AMPK-mediated phosphorylation lower cAMP\textsuperscript{21}. Furthermore, metformin via AMPK-mediated phosphorylation of AQP2 enhances its accumulation in the apical membrane and reduces the aquaretic effect of tolvaptan\textsuperscript{22}. Currently, two phase 2 studies are investigating the effect of metformin treatment on disease progression in ADPKD (Clinicaltrial.gov Identifiers: NCT02656017 and NCT02903511).

Statins and tetracycline antibiotics demeclocycline and doxycycline may also have synergistic effects with tolvaptan. Statins may lower cAMP through downregulation of G\textsubscript{a}s protein\textsuperscript{23} and induce membrane accumulation of AQP2 via inhibition of endocytosis,\textsuperscript{24} thus reducing aquarexis. Demeclocycline decreases adenylate cyclase 5/6 expression and, consequently, cAMP generation\textsuperscript{25}. In animal studies doxycycline significantly decreased renal tubule cell proliferation and inhibited cystic disease progression in rats orthologous to human ARPKD\textsuperscript{26}. However, the nephrotoxicity of these drugs when used at high doses may limit their potential for the treatment of PKD; for example, doxycycline at a high dose was found to aggravate cyst growth and fibrosis in a mouse model of type 3 nephronophthisis\textsuperscript{27}.

WATER INTAKE

Lowering vasopressin concentration and slowing disease progression in PKD by increasing water intake has been a topic of studies for many years. It should be noted that the effects of V2R antagonists and enhanced hydration are not identical (Table 1). Promising effects of increased water intake have been found by Nagao et al., who found in rats orthologous to human ARPKD that a high water intake decreased urinary vasopressin excretion by 68.3\%, and the renal expression of vasopressin V2 receptors was decreased. High water intake slowed disease progression in both male and female rats, decreased kidney-to-body weight-ratio 29.8 and 27.0\% respectively, and reduced serum urea nitrogen in the male rats from 38.7 to 26.3 mg/dl\textsuperscript{28}. Similar results were obtained by Hopp et al. in the same rat model,\textsuperscript{29} but not in a Pkd1 mouse model. In these rats, a fourfold increase in urine output led to reductions in urine vasopressin and renal levels of cAMP, with a marked protective effect on the development of PKD, as reflected by lower kidney weights, plasma urea, and cystic and fibrotic indexes\textsuperscript{30}.
Polycystic kidney disease and the vasopressin pathway

When studying the effects of increased water intake in human ADPKD, the beneficial effects on disease progression have not yet been confirmed. In a pilot clinical study by Barash et al., 13 ADPKD patients were instructed to increase their water intake for seven days, resulting in average intake of 3.1 L/day. This caused a significant urine osmolality decline of 46% to 270 mOsm/L (P=0.04), lowering it below plasma osmolality, and thus likely causing a decreased vasopressin concentration (not measured). Higashihara et al. performed a study in 34 patients with ADPKD who received either a high or free water intake during one year, leading to mean 24-hour urine volumes of 2.6 versus 1.4 liter per day (P<0.001).

Table 1. Different effects of V2R antagonists and enhanced hydration (Bankir et al.2)

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Increase fluid intake</th>
<th>V2R antagonists</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient behavior</td>
<td>Voluntary frequent drinking</td>
<td>Taking a pill</td>
</tr>
<tr>
<td>Adherence to treatment</td>
<td>Poor (difficult to drink without thirst)</td>
<td>Good (easy)</td>
</tr>
<tr>
<td>Plasma osmolality</td>
<td>Decreased</td>
<td>Increased</td>
</tr>
<tr>
<td>Vasopressin secretion and plasma level</td>
<td>Decreased</td>
<td>Increased</td>
</tr>
<tr>
<td>Vasopressin effects mediated by other receptors (V1aR and V1bR) *</td>
<td>Reduced</td>
<td>Enhanced</td>
</tr>
<tr>
<td>Possible side effects</td>
<td>Aversion to water, frequent need to urinate, risk of hyponatraemia</td>
<td>Thirst, frequent need to urinate, risk of dehydration</td>
</tr>
<tr>
<td>Financial costs</td>
<td>None</td>
<td>High</td>
</tr>
</tbody>
</table>

V1aR, vasopressin V1a receptor; V1bR, vasopressin V1b receptor
* Note that enhanced V1aR-mediated actions may not be harmful as is usually feared
Chapter 2

Figure 1. Intracellular signaling in tubular cells of the collecting duct in ADPKD, and the role of vasopressin.
Polycystic kidney disease and the vasopressin pathway

Plasma AVP and copeptin were, as expected, lower in the high water intake group (both P=0.02). However, non-significant trends towards faster eGFR decline (-5.6 mL/min/1.73m² vs. -1.1, P=0.06) and total kidney volume (TKV) growth (9.68 %/year vs. 5.28, P=0.08), rather than a beneficial effect, were observed in the high compared to the free water intake31. Finding no beneficial effects of an increased water intake in this study might have been due to shortcomings of the study design. First, the study had only 34 participants, potentially leading to an underpowered statistical analysis. Second, for assessment of the primary endpoint, historical data was used. Third, participants were not randomized, but could enroll in the group they preferred, potentially leading to a selection bias, as is reflected by a significantly higher 24-hour urine volume in the high water intake group at baseline. Finally, the high water intake group was instructed to drink - 50 mL water/kg body weight/day (2.5–3.0 L of water/day) or more, mostly during the first half of the day, which might not be enough to change the disease course and show a beneficial effect.

These inconclusive results suggest a need for future randomized controlled trials which study the effect of an increased fluid intake on disease progression in CKD and PKD in particular. Currently, there is an ongoing trial studying the effect of an increased fluid intake of 1-1.5L/day in CKD (Clinicaltrial.gov Identifier: NCT01766687), and another clinical trial in 180 ADPKD patients, of which half will have prescribed fluid intake to reduce urine osmolality to ≤270 mOsm/kg32.

DIETARY FACTORS

Besides water intake, other lifestyle factors might influence the disease course of PKD by lowering the vasopressin concentration (Table 2). The recommendations in the KHA-CARI ADPKD Guideline for diet and lifestyle management are based on lifestyle modifications that have proven to be effective in management of early CKD progression, as there is no evidence specific to ADPKD that would alter these recommendations. It includes a moderate protein diet (0.75-1.0 g/ kg/day), a restricted dietary sodium intake to 100 mmol/day (i.e. 2.3 g sodium or 6 g salt) or less, to drink fluid to satisfy thirst, and to stop or not start smoking33.

In a large general population cohort, we previously found that a higher copeptin concentration was cross-sectionally associated with lower water intake (measured as 24-hour urine volume), higher 24-hour sodium and urea excretion (in steady state markers of sodium and protein intake), a lower 24-hour potassium excretion, higher number of cigarettes smoked, as well as alcohol use and higher number of alcoholic consumptions34.
Chapter 2

Non-linear relations between copeptin concentration and body mass index, as well as plasma glucose concentration, were observed.

In the CRISP study, involving 241 patients with ADPKD, high urine osmolality (a marker for AVP activity), high urine sodium excretion (a marker for sodium intake) and low serum HDL-cholesterol were associated with the rates of TKV increase and eGFR decline\[^35\]. In a recent post hoc analysis of the HALT-PKD clinical trials, dietary sodium – measured as averaged sodium excretion – showed to be associated with the rate of TKV increase, but not with the rate of eGFR decline in ADPKD patients with an eGFR over 60 ml/min/1.73 m\(^2\). In patients with an eGFR 25-60 ml/min/1.73 m\(^2\) averaged sodium excretion was associated with reaching a composite endpoint of 50% reduction of eGFR, ESRD or death, and with a faster rate of eGFR decline\[^36\]. Markers of vasopressin were not studied in the HALT-PKD trials.

Protein intake, both a single meal and chronic high intake, is known to directly increase the circulating vasopressin concentration and simultaneously GFR. It changes the urea handling by the renal tubule, as the fractional excretion of urea is increased following a protein meal, and is thought to participate in glomerular hyperfiltration and kidney hypertrophy\[^37\]. As reviewed in the KHA-CARI Guideline, the only study investigating protein intake in ADPKD was a secondary analysis of the MDRD Study analyzing 200 patients with ADPKD, where they found no clear benefit of low protein intake and decline in GFR. Meta-analyses in chronic kidney disease indicate either no effect or a modest benefit of protein-restricted diets\[^33\].

Recently, a very promising pilot study treated 34 ADPKD patients with a low osmolar, water-adjusted diet and observed a lower copeptin concentration on this dietary regime. Patients received a low sodium (1,500 mg/d), low protein (daily protein dietary allowance, 0.8 g/kg body weight), and low urea (i.e., avoidance of preservatives, food additives, bulking agents, and chewing gum) diet, combined with an individually-adjusted water intake, to ensure urine osmolality of 280 mOsm/kg or lower. After two weeks of treatment, patients had significantly lower plasma copeptin levels compared to non-treated patients (6.2±3.05 versus 5.3±2.5pmol/L, respectively; P=0.02). Total urinary solute decreased in only the intervention group and significantly differed between groups at week 1 (P=0.03)\[^38\].
**Polycystic kidney disease and the vasopressin pathway**

**OTHER (LIFESTYLE) FACTORS**

Hypothetically, caffeine has a specific deleterious effect in PKD via phosphodiesterase (PDE) inhibition, but when analyzing the effects of caffeine intake in a case-control study in 102 ADPKD patients, no associations were found between coffee intake and eGFR or TKV\(^3\). However, the majority of these patients (63%) had previously been advised to lower coffee consumption, and the mean coffee intake was significantly lower compared to healthy controls (86±77 vs 134±116 mg/day, \(P \leq 0.001\))\(^3\).

Nicotine is known to have an antidiuretic effect and causes an increased vasopressin concentration. A history of smoking and pack-year of cigarettes smoked, were significantly associated with rapid disease progression in ADPKD\(^4\). In ADPKD patients, smoking also correlated with proteinuria and an increased risk of progression to end-stage renal disease (ESRD)\(^5\). A recent mouse study in *Pkd1* mice revealed that smoking aggravated the renal phenotype of these mice, thereby supporting the theoretical accelerating effect of smoking on PKD-progression\(^6\).

Vasopressin was associated with obesity, metabolic syndrome and diabetes mellitus in the Malmö Diet and Cancer Study cardiovascular cohort (n=2,064)\(^7\). In a separate, small case-control study in subjects with preserved renal function, the presence of ADPKD was associated with components of metabolic syndrome such as hypertension, abdominal obesity and higher fasting glycaemia\(^8\). Markers of vasopressin concentration were not studied.


**Table 2. Studies that suggest an association between lifestyle factors and polycystic kidney disease progression.**

<table>
<thead>
<tr>
<th>Study</th>
<th>Model</th>
<th>Lifestyle</th>
<th>Study type</th>
<th>Outcome measure(s)</th>
<th>Main findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nagao et al. (2006)⁸⁸</td>
<td>Rats orthologous to human ARPKD</td>
<td>Water intake</td>
<td>Interventional animal study</td>
<td>Urinary AVP excretion, AVP V2 receptor expression, kidney-to-body-weight (%), SUN</td>
<td>Urinary AVP excretion decreased 68.3%, AVP V2 receptor expression normalized under high water intake, kidney-to-body-weight decreased 29.8% and 27.0% in male and female rats, respectively, and SUN decreased from 38.7 to 26.3 mg/dl in the male rats.</td>
</tr>
<tr>
<td>Hopp et al. (2015)⁹³</td>
<td>Rats ortholog. to human ARPKD and Pkd1⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻帔</td>
<td>Urine output was increased by 4-fold and all studied parameters were lower in rats on a high water intake. Despite a more than 7-fold increased urine output in Pkd1⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻⁻ Hentai</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Barash et al. (2010)⁹⁰</td>
<td>ADPKD patients</td>
<td>Water intake</td>
<td>Interventional study</td>
<td>24-hour urine volume, urine osmolality</td>
<td>24-hour urine volume increased 6.4% (to 3.1 L), urine osmolality decreased 46% (to 270±21 mOsm/L).</td>
</tr>
<tr>
<td>Higashihara et al. (2014)⁹¹</td>
<td>ADPKD patients</td>
<td>Water intake</td>
<td>Interventional study</td>
<td>Plasma AVP and copeptin, eGFR decline, TKV growth</td>
<td>Plasma AVP and copeptin lower in high (HW) versus low water (LW) intake (both P=0.02), whereas no effect on eGFR decline (mL/min/1.73m²), being -5.6 HW vs. -1.1 LW (P=0.06) or TKV growth (9.68 HW vs. 5.28 LW; P=0.08) were observed.</td>
</tr>
<tr>
<td>Torres et al. (2011)⁹⁵</td>
<td>ADPKD patients</td>
<td>Sodium and protein intake, HDL-chol., BSA, BMI</td>
<td>Multicenter study, case series</td>
<td>TKV slope and eGFR decline</td>
<td>Excretion and low serum HDL-cholesterol were associated with TKV and eGFR slopes. Also baseline BSA, BMI, and estimated protein intake were associated with TKV increase over time.</td>
</tr>
<tr>
<td>Torres et al. (2016)⁹⁶</td>
<td>ADPKD patients</td>
<td>Sodium intake (as sodium excretion)</td>
<td>Post hoc analysis</td>
<td>TKV growth, eGFR change and risk to reach composite endpoints</td>
<td>Urine sodium excretion was significantly associated with TKV growth (P&lt;0.001), and an non-significant trend for eGFR decline (P=0.09). Averaged urine sodium excretion was significantly associated with eGFR decline (P&lt;0.001) with risk to reach the composite end-point of 50% reduction in eGFR, ESRD or death.</td>
</tr>
<tr>
<td>Study</td>
<td>Model</td>
<td>Lifestyle</td>
<td>Study type</td>
<td>Outcome measure(s)</td>
<td>Main findings</td>
</tr>
<tr>
<td>------------------</td>
<td>------------------------</td>
<td>-----------------------------------------------</td>
<td>-------------------------------------</td>
<td>--------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Amro et al.</td>
<td>ADPKD patients</td>
<td>Low osmolar diet and adjusted water intake</td>
<td>Randomized controlled trial (pilot)</td>
<td>Plasma copeptin, urine osmolality, and total urinary solute</td>
<td>Mean plasma copeptin levels and urine osmolality declined from 6.2±3.05 to 5.3±2.5 pmol/L (P=0.02) and from 426±193 to 258±173 Osm/kg water (P=0.01), respectively in the intervention group. Total urinary solute decreased in only the intervention group and significantly differed between groups at week 1 (P=0.03).</td>
</tr>
<tr>
<td>Vendramini et al.</td>
<td>ADPKD patients</td>
<td>Caffeine</td>
<td>Cross-sectional study</td>
<td>eGFR, TKV, hypertension</td>
<td>Mean caffeine intake was significantly lower in ADPKD patients versus controls (86 vs 134 mg/day). No significant differences for tertiles of coffee intake and eGFR, TKV or hypertension.</td>
</tr>
<tr>
<td>Ozkok et al.</td>
<td>ADPKD patients</td>
<td>Clinical characteristics like smoking, hypertension and proteinuria</td>
<td>Historical prospective study</td>
<td>Decline in GFR</td>
<td>Rapidly progressing patients had significantly higher history of smoking (36 versus 18%, P=0.01) and pack years of smoking. A Cox regression did not confirm that smoking predicted progression of CKD in ADPKD patients (P=0.63), whereas age, presence of hepatic cysts, hypertension and proteinuria did (P=0.01, P=0.001, P=0.04 and P=0.02, respectively).</td>
</tr>
<tr>
<td>Orth et al.</td>
<td>ADPKD patients</td>
<td>Smoking</td>
<td>Case-control study</td>
<td>Progression to ESRD</td>
<td>In smoking men (average pack years 16.9±2.0), a significant dose-dependent increase of the risk to progress to ESRD compared to controls (average pack years 8.2±4.9) was found (P=0.001).</td>
</tr>
<tr>
<td>Veloso Sousa et</td>
<td>Pkd1-deficient mice</td>
<td>Smoking</td>
<td>Interventional animal study</td>
<td>SUN, cystic index, renal fibrosis and cell proliferation</td>
<td>In Pkd1-mice, smoking increased SUN (57.2±32.4 vs 35.7±6.0 mg/dL, p&lt;0.05), the cystic index (17.4 vs 4.6%; P&lt;0.05), renal fibrosis (1.1 vs 0.3%; P&lt;0.0001) and cell proliferation in cystic epithelia (2.1 vs 1.1%; P&lt;0.05).</td>
</tr>
</tbody>
</table>

Abbreviations: ARPKD, Autosomal Recessive Polycystic Kidney Disease; AVP, Arginine Vasopressin; SUN, serum urea nitrogen; cAMP, cyclic adenosine monophosphate; ADPKD, Autosomal Dominant Polycystic Kidney Disease; eGFR, estimated glomerular filtration rate; TKV, total kidney volume; HDL, high-density lipoproteins; BSA, body surface area; BMI, body mass index; ESRD, end-stage renal disease
Chapter 2

CONCLUSIONS

It is important that future studies focus on the relationship between increased fluid consumption and lowering osmolar intake on vasopressin concentration, and most importantly the progression of PKD. If future research determines that reducing vasopressin concentration leads to slowed disease progression, other lifestyle factors, like smoking and obesity, should be studied because they are associated with increased vasopressin concentrations.

ACKNOWLEDGEMENTS

VET received from Danone Research the reimbursement of travel expenses and registration fee to attend the H4H Scientific Conference.
Polycystic kidney disease and the vasopressin pathway

REFERENCES

Chapter 2


